BioStock: Annexin: Could ANXV replace anti-VEGFs?

Annexin Pharmaceuticals is developing the drug candidate ANXV in the eye disease retinal vein occlusion, RVO, as well as in cancer. Recently, the company released phase IIa topline results from its study in RVO. Annexin visited BioStock’s studio to talk more about the results and the plan going forward.
– The results are as good as we could have ever hoped for, says CEO Anders Haegerstrand.

Watch the interview with CEO Anders Haegerstrand and CMO/CSO Anna Frostegård at biostock.se:

https://www.biostock.se/en/2024/08/annexin-pharmaceuticals-could-anxv-replace-anti-vegfs/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se